Abstract
Because in vitro data suggest that mitoxantrone may be synergistic with cisplatin, a Phase II trial of mitoxantrone and cisplatin was conducted in patients with advanced or metastatic non-small-cell lung cancer (NSLC). Twenty-four patients were evaluable for response. Toxicity was tolerable. Partial response occurred in three patients (13%). This response rate is similar to that reported for cisplatin alone in NSLC. Mitoxantrone did not improve the response rate when combined with cisplatin for patients with advanced NSLC.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / secondary
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Brain Neoplasms / secondary
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / secondary
-
Cisplatin / administration & dosage*
-
Cisplatin / adverse effects
-
Drug Synergism
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Mitoxantrone / administration & dosage*
-
Mitoxantrone / adverse effects
-
Neoplasm Staging
-
Remission Induction
-
Survival Rate
Substances
-
Antineoplastic Agents
-
Mitoxantrone
-
Cisplatin